<p>A total of 24 HIV-negative volunteers were vaccinated with MVA-B in the RISVAC02 study. Four years later, 13 of these volunteers were recruited to receive a single intramuscular boost of MVA-B vaccination in the RISVAC02boost clinical trial. Adverse Events (AEs), laboratory analyses and immunogenicity endpoints were tested as scheduled in the flow chart.</p
<p>CONSORT 2010 Flow Diagram. The schema graphically outlines the design and conduct of the clinical...
Background: VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active a...
Participants were vaccinated three times at 0,1,6 months with Hepatitis B or Na-GST-1 plus Na-APR-1 ...
<p>(A) A total of 31 volunteers were randomized (21 to the MVA-B arm and 10 to the placebo arm) but ...
We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia ...
<p>Of 242 screened volunteers, 120 subjects were assessed eligible for enrollment, allocated to one ...
International audienceBackground: Our previous work has demonstrated the benefits of transcutaneous ...
<p>All vaccinations were administered intramuscularly. ChAd63 AMA1 was administered on day 0 and MVA...
<p>All subjects screened, enrolled and randomized are indicated in the chart. A total of 24 subjects...
TRIAL DESIGN: Previous studies suggested that poxvirus-based vaccines might be instrumental in the t...
<p>Thirty-seven volunteers met all eligibility criteria and were allocated to the immunization group...
Accelerating clinical development of HIV vaccine proportion, without direct comparisons between arms...
<p>The flow chart depicts the naïve HIV-infected patients enrolled in the study from two health cent...
<p>(A) Percentage of MDDCs internalizing Env in the presence of sera from trial subjects (n = 7) at ...
<p>Subjects positive for HBsAg and/or HBV-DNA were considered carriers of HBV. Subjects positive for...
<p>CONSORT 2010 Flow Diagram. The schema graphically outlines the design and conduct of the clinical...
Background: VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active a...
Participants were vaccinated three times at 0,1,6 months with Hepatitis B or Na-GST-1 plus Na-APR-1 ...
<p>(A) A total of 31 volunteers were randomized (21 to the MVA-B arm and 10 to the placebo arm) but ...
We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia ...
<p>Of 242 screened volunteers, 120 subjects were assessed eligible for enrollment, allocated to one ...
International audienceBackground: Our previous work has demonstrated the benefits of transcutaneous ...
<p>All vaccinations were administered intramuscularly. ChAd63 AMA1 was administered on day 0 and MVA...
<p>All subjects screened, enrolled and randomized are indicated in the chart. A total of 24 subjects...
TRIAL DESIGN: Previous studies suggested that poxvirus-based vaccines might be instrumental in the t...
<p>Thirty-seven volunteers met all eligibility criteria and were allocated to the immunization group...
Accelerating clinical development of HIV vaccine proportion, without direct comparisons between arms...
<p>The flow chart depicts the naïve HIV-infected patients enrolled in the study from two health cent...
<p>(A) Percentage of MDDCs internalizing Env in the presence of sera from trial subjects (n = 7) at ...
<p>Subjects positive for HBsAg and/or HBV-DNA were considered carriers of HBV. Subjects positive for...
<p>CONSORT 2010 Flow Diagram. The schema graphically outlines the design and conduct of the clinical...
Background: VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active a...
Participants were vaccinated three times at 0,1,6 months with Hepatitis B or Na-GST-1 plus Na-APR-1 ...